EUVIMEDEUVIMED entdecken
Crossref

Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway

European Journal of Gynaecological Oncology · 2022

DOI: 10.22514/ejgo.2022.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Gynaecological Oncology, 2022. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitexin is widely known as a bioactive flavonoid compound, and exerts analgesic and anti-oxidative properties. Antitumor effect of vitexin was identified in various tumors. Role and related mechanism of vitexin in cervical cancer were investigated. Cervical cancer cells were treated with vitexin, and treatment with vitexin reduced cell viability, and decreased number of colonies in cervical cancer. Moreover, cell migration and invasion were repressed by vitexin, and vitexin inhibited angiogenesis of cervical cancer. Vitexin reduced protein expression of Vascular Endothelial Growth Factor A (VEGFA) and Vascular endothelial growth factor receptor 2 (VEGFR2) of cervical cancer in a dosage dependent way. In conclusion, vitexin reduced cell proliferation, migration, invasion and angiogenesis of cervical cancer through inhibition of VEGFA/VEGFR2 signaling.

Zitieren

APA

(2022). Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway. European Journal of Gynaecological Oncology. https://doi.org/10.22514/ejgo.2022.036

Vancouver

Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway. European Journal of Gynaecological Oncology. 2022. doi:10.22514/ejgo.2022.036

BibTeX
@article{euvimed2022,
  title = {Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway},
  journal = {European Journal of Gynaecological Oncology},
  year = {2022},
  doi = {10.22514/ejgo.2022.036}
}
Kostenlos starten →